We analyze cellular response to both biological and process related perturbations, including LNPs, viral vectors, gene edits, media and formulation conditions, and manufacturing related stresses. Sample types include patient derived and donor derived cellular material, adherent or suspension cell lines, primary cells, cell banks used for fit-for-purpose qualification assessments, and complex bioprocess cultures across upstream and downstream workflows.

No, you do not. Many scientists take advantage of LumaCyte’s laboratory services initially to gain valuable data on their process and cell systems before acquiring and installing a Radiance® unit in their laboratory or manufacturing suite.

Yes. Our bioanalytical data engineering team can be engaged as an outsourced biostatistics and modeling resource to support Radiance® and LFC data generated in your laboratory. We work directly with your datasets to optimize methods, build predictive and multivariate models, and ensure analytics outputs are efficiently translated into meaningful process, quality, and decision-making insights without requiring you to outsource sample analysis.

By integrating high resolution cellular fingerprints with LFC multivariate and machine learning models, we generate early insight into cellular response that would otherwise emerge much later in development or manufacturing. This enables rapid process optimization, improved understanding of process and product relationships, and earlier identification of variability, potency, and quality risks compared to traditional assays. Standardizing on advanced analytical methods further supports robust regulatory assurance strategies, while enabling streamlined technical transfer and comparability across sites and programs, driving greater efficiency and confidence throughout the product lifecycle.

Yes. Radiance® quantitative, label‑free measurements support comparability, PAT alignment, and comprehensive data packages for IND, BLA, and technical transfer documentation. FDA guidance on potency and advanced therapy CMC encourages mitigating variability in starting materials and the use of in‑process analytics early and throughout development to ensure robust process understanding and control. LumaCyte’s laboratory and data services enable early, standardized cellular insights using advanced analytics, supporting strong regulatory assurance strategies and improving the quality, consistency, and comparability of regulatory submissions.

Initial results are typically available within days to weeks, with timelines driven by study scope, sample volume, sample diversity, and modeling requirements.

Yes. Our predictive variability and early divergence analyses identify subtle shifts in cellular response that precede observable process failure or performance loss. By resolving how cells respond to biological inputs, process conditions, and manufacturing stresses, we help pinpoint when and where variability is emerging across development or production. These insights provide developers with a clear, data‑driven starting point for root cause investigation, process refinement, and control strategy adjustments, reducing trial‑and‑error and accelerating resolution of complex or unstable processes.

Absolutely. Our team remains engaged throughout the program with regular working meetings, continuous data updates, and expert scientific interpretation. This ensures stakeholders stay aligned and informed while supporting consistent decision making across single‑phase studies, multi‑phase development programs, and ongoing manufacturing efforts.